Pharmaceutical

Sandoz partners with Samsung Bioepis to license Stelara biosimilar

The agreement allows Sandoz exclusive marketing rights for the inflammatory bowel disease therapy in Europe and North America.

Sep 11, 2023 - 20:00
Sandoz partners with Samsung Bioepis to license Stelara biosimilar
The agreement allows Sandoz exclusive marketing rights for the inflammatory bowel disease therapy in Europe and North America.
Read the original article

Tags:

Previous Article

STAT+: Crinetics acromegaly drug succeeds in late-stage trial but would face sti...

Next Article

Pharmaceutical Technology Excellence Awards 2023: Viedoc

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: House panel passes public health bills following contentious debate

STAT+: House panel passes public health bills following...

Jul 14, 2023

MOMA Therapeutics and Roche sign cancer drug discovery deal

MOMA Therapeutics and Roche sign cancer drug discovery ...

Jan 5, 2024

The WHO and drug regulators want to reformulate the flu vaccine. It’s easier said than done

The WHO and drug regulators want to reformulate the flu...

Jan 16, 2024